
|Videos|May 2, 2022
Unpacking the need to accelerate clinical studies in retina
Author(s)David Hutton, Emily Kaiser Maharjan
Dr David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Advertisement
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
2
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
5













































